14 GHP Biotechnology & Lifesciences Awards 2025 ince its establishment in 2018, Mestastop has been dedicated to finding treatment for metastatic cancer, working tirelessly to help medical oncologists delay metastasis through the development of small molecules and diagnostics. Currently, approximately 90% of cancer patients die from metastatic illness, making it the leading cause of cancer-related death and linked to poor patient prognosis, yet the standard therapies do not prevent nor cure metastasis. Most patients experiencing advanced-stage or high-risk tumours still pass away from metastatic disease or treatment-related problems, even with the advanced development of new therapies in the last two decades. Data from recent publications suggest that most cancer medications approved by the FDA have had little to no impact on quality of life, progression-free survival, or overall survival. Mestastop believes that a significant increase in these areas is only possible when metastasis is prevented. When all other clinical trials towards targeted anti-metastatic agents have failed, Mestastop takes an alternative approach to its operations, employing reverse translational biology that starts from patient tumour-based data and connecting it with individual patients’ follow-up survival and metastasis data to understand the biology of metastasis and identify novel first-in-class targets. This bedside-to-bench approach is the differentiator of Mestastop’s platforms. Its platforms are based on clinical patient data and help identify the key rate-limiting steps in the metastasis process. “In contrast to the initial understanding that dissemination was mostly responsible for metastasis, Mestastop data suggests that the ability of disseminated cells to adapt in the secondary microenvironment plays an important role,” Arnab states. “Mestastop assumes that cells have already disseminated during the diagnosis of primary tumours and focuses on preventing these cells from adapting in AIS-Feb25012 S Metastatic cancer is responsible for approximately 90% of cancer deaths. Often referred to as stage 4 cancer, metastasis occurs when cancer cells spread from the primary site to other parts of the body, travelling through the bloodstream or lymphatic system to reach distant organs or tissues. Mestastop Solutions is a leading company focused on developing treatments for metastatic cancer, specialising in drug discovery and predictive diagnostics to address cancer metastasis as early as possible. Here, we speakwithArnabRoyChowdhury,Founder and Director of Mestastop Solutions, to learn more about the company’s exceptional endeavours. the secondary microenvironment. Based on this understanding, we have identified three novel first-in-class targets playing a critical role in the adaption biology.” To remain a leader in this dynamic field, Mestastop Solutions is meticulous in its operations, working closely with a Tumour Review Board and internal ethics committee when sourcing tumours for research. It obtains individual consent forms to ensure that each patient is informed and agrees to the use of their tumour samples for research purposes. What’s more, the company adheres to all protocols related to animal safety and wellbeing throughout its research and has all cell and molecular biology work approved by an internal biosafety committee, ensuring that its research practices consistently meet safety standards and regulations. Mestastop Solutions maintains such high standards of operations due to the exceptional team driving its research. The company comprises 16 professionals, six of whom possess PhDs, and is dedicated to curating a productive, innovative internal culture. When expanding the team, Mestastop Solutions seeks out individuals possessing scientific integrity, attention to detail, motivation, the ability to be a team player, and precise and clear communication skills. These qualities are essential for prosperity in the rapidly advancing landscape of oncology and guarantee sustained success for Mestastop Solutions as it continues to champion effective treatment for metastasis. “Science thrives in a non-hierarchical system, where everyone is treated equally and any ideas can be great, irrespective of the person or his seniority,” says Arnab. “Mestastop Solutions has built a team that rallies around themselves by imbibing a culture of celebrating each other’s success and fostering open innovation. Additionally, the team is self-critical and does not fall in love with their ideas; they are bold in their vision but are critical and ruthless in their interpretation. Mestastop Solutions lets science do the talking.” Moving forward, we learn that Mestastop has a year of innovation ahead. In 2025, the company plans to start the Investigational New Drug filing process with the FDA for its phase III repurposing clinical trial candidate. Additionally, it intends to hire a Chief Business Officer in the USA, who will bring more than three decades of experience in pharmaceutical drug discovery and deal-making to the team. This strategic move will bolster Mestastop’s clinical trial efforts and propel the company forward on its mission of developing successful treatment for metastatic cancer. Contact: Arnab Roy Chowdhury Company: Mestastop Solutions Pvt Ltd Web Address: https://mestastop.com/ Best Metastasis R&D Specialist 2025 & GHP Innovation Excellence Award 2025
RkJQdWJsaXNoZXIy NTY1MjM3